Drug Profile
Labuvirtide - Frontier Biotechnologies
Alternative Names: Aikening; Albuvirtide - Frontier Biotechnologies; FB-006MLatest Information Update: 19 Jan 2023
Price :
$50
*
At a glance
- Originator Frontier Biotechnologies
- Class Antivirals; Maleimides; Peptides
- Mechanism of Action HIV envelope protein gp41 inhibitors; HIV fusion inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - HIV-1 infections
Highest Development Phases
- Registered HIV-1 infections
- No development reported HIV infections
Most Recent Events
- 25 Jan 2022 Frontier Biotechnologies plans a phase I trial for HIV infections in China (IV, Injection, Infusion) (NCT05206019)
- 19 Jul 2021 Safety and efficacy data from the phase III TALENT study in HIV-1 infections released by Frontier Biotechnologies
- 19 Jul 2021 Frontier Biotechnologies plans additional clinical trials for HIV-1 infections (Combination therapy) (IV, Infusion)